Literature DB >> 31090265

Role of SIRT1 in hematologic malignancies.

Fei-Teng Huang1,2, Jie Sun1, Lei Zhang2, Xin He1, Ying-Hui Zhu1, Hao-Jie Dong1, Han-Ying Wang1, Lei Zhu1, Jing-Ying Zou1, Jin-Wen Huang2, Ling Li1.   

Abstract

Sirtuin 1 (SIRT1) is a protein deacetylase, which regulates various physiological activities by deacetylating different protein substrates. An increasing number of studies have revealed critical roles of SIRT1 in different aspects of cancers including metabolism, proliferation, genomic instability, and chemotherapy resistance. Depending on the protein targets in a certain oncogenic context, SIRT1 may play a unique role in each individual blood cancer subtype. Our previous work showed that activation of SIRT1 in primitive leukemia cells of acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) promotes disease maintenance. On the other hand, an SIRT1 agonist was shown to disrupt maintenance of myelodysplastic syndrome (MDS) stem cells and holds promise as a potential therapeutic approach. Herein, we present a concise summary of the different functions of SIRT1 in hematologic malignancies.

Entities:  

Keywords:  Sirtuin 1 (SIRT1); Hematologic malignancy; Stem cell; Drug resistance

Mesh:

Substances:

Year:  2019        PMID: 31090265      PMCID: PMC6568226          DOI: 10.1631/jzus.B1900148

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  43 in total

Review 1.  Acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; Mary V Relling; James R Downing
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

Review 2.  Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Authors:  Ruibao Ren
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

3.  Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.

Authors:  Chuangui Wang; Lihong Chen; Xinghua Hou; Zhenyu Li; Neha Kabra; Yihong Ma; Shino Nemoto; Toren Finkel; Wei Gu; W Douglas Cress; Jiandong Chen
Journal:  Nat Cell Biol       Date:  2006-08-06       Impact factor: 28.824

4.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

Authors:  C A Bradbury; F L Khanim; R Hayden; C M Bunce; D A White; M T Drayson; C Craddock; B M Turner
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

5.  Negative control of p53 by Sir2alpha promotes cell survival under stress.

Authors:  J Luo; A Y Nikolaev; S Imai; D Chen; F Su; A Shiloh; L Guarente; W Gu
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

6.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

7.  Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.

Authors:  Birgit Heltweg; Tonibelle Gatbonton; Aaron D Schuler; Jeff Posakony; Hongzhe Li; Sondra Goehle; Ramya Kollipara; Ronald A Depinho; Yansong Gu; Julian A Simon; Antonio Bedalov
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

8.  A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy.

Authors:  In Hye Lee; Liu Cao; Raul Mostoslavsky; David B Lombard; Jie Liu; Nicholas E Bruns; Maria Tsokos; Frederick W Alt; Toren Finkel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

9.  Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.

Authors:  Rui-Hong Wang; Kundan Sengupta; Cuiling Li; Hyun-Seok Kim; Liu Cao; Cuiying Xiao; Sangsoo Kim; Xiaoling Xu; Yin Zheng; Beverly Chilton; Rong Jia; Zhi-Ming Zheng; Ettore Appella; Xin Wei Wang; Thomas Ried; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

10.  SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.

Authors:  Kyu Yun Jang; Sung Ho Hwang; Keun Sang Kwon; Kyung Ryoul Kim; Ha Na Choi; Na-Ri Lee; Jae-Yong Kwak; Byung-Hyun Park; Ho Sung Park; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Hun Soo Kim; Hyeok Shim; Woo Sung Moon
Journal:  Am J Surg Pathol       Date:  2008-10       Impact factor: 6.394

View more
  4 in total

1.  The anti-tumour effect of induced pluripotent stem cells against submandibular gland carcinoma in rats is achieved via modulation of the apoptotic response and the expression of Sirt-1, TGF-β, and MALAT-1 in cancer cells.

Authors:  Eman Mohamed Faruk; Dina Sabry; Ahmed A Morsi; Yasmine Alaa El-Din; Neama M Taha; Engy Medhat
Journal:  Mol Cell Biochem       Date:  2021-09-17       Impact factor: 3.396

2.  miR-27a promotes osteogenic differentiation in glucocorticoid-treated human bone marrow mesenchymal stem cells by targeting PI3K.

Authors:  Jinshan Tang; Huaixi Yu; Yunqing Wang; Gang Duan; Bin Wang; Wenbo Li; Ziqiang Zhu
Journal:  J Mol Histol       Date:  2021-02-02       Impact factor: 2.611

3.  Sirtuin 1 inhibits lipopolysaccharide-induced inflammation in chronic myelogenous leukemia k562 cells through interacting with the Toll-like receptor 4-nuclear factor κ B-reactive oxygen species signaling axis.

Authors:  Lei Wang; Mingming Wang; Hongju Dou; Wenjie Lin; Lifang Zou
Journal:  Cancer Cell Int       Date:  2020-03-06       Impact factor: 5.722

4.  Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.

Authors:  Stephanie Seneff; Greg Nigh; Anthony M Kyriakopoulos; Peter A McCullough
Journal:  Food Chem Toxicol       Date:  2022-04-15       Impact factor: 5.572

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.